MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Zimmer slides on Q1 results | Earnings Roundup

Zimmer slides on Q1 results | Earnings Roundup

By

MassDevice.com Earnings Roundup

Investors sent shares of Zimmer (NYSE:ZMH) down 5% this morning in pre-market trading after the orthopedic device maker reported sales and earnings in-line with Wall Street’s expectations, but lackluster sales of hip and knee implants.

The Warsaw, Ind.-based company posted profits of $209.6 million, or $1.17 per diluted share, on sales of $1.14 billion for the 3 months ended March 31.

That’s a bottom-line gain of less than 1% and a top-line addition of 2.2%, compared with profits of $208.9 million, or $1.08 diluted EPS, on sales of $1.12 billion during Q1 2011. Diluted EPS rose 8.3% year-over-year.

"Zimmer delivered year-over-year sales growth in all geographic segments and in most product categories in the quarter," president & CEO David Dvorak said in prepared remarks. "Looking forward, our new product introductions and progress in our transformation programs will enable the Company to generate increased value to stockholders."

Overall sales of joint reconstruction products rose 2% to $860 million, with most of that growth coming from the Asia-Pacific region. U.S. recon sales growth was flat, as were the revenue figures for domestic sales of knee and hip implants, at $468 million, $279 million and $154 million, respectively.

"We think some may be a bit disappointed that US hip/knee growth did not show as much of a sequential y/y growth acceleration this quarter as some may have been expecting, especially in knees,” wrote Leerink Swann analyst Richard Newitter in a note to investors this morning. “This reinforces our view that US ortho recon markets have likely bottomed and remain stable, possibly even beginning to show some early signs of improvement. However, we still think it’s too early to call an inflection point for a procedure volume recovery.”

Zimmer lowered its 2012 sales guidance to growth of between 0% and 2.5%, saying it expects foreign exchange rates to cut the top line by between 1.5% and 2%. Its prior guidance predicted FX to cut about 1% from revenues.

Diluted EPS are forecast to run between $4.70 and $4.90, down from $4.75 to $4.95.

ZMH shares opened today at $61.20, down 3.5% from yesterday’s $63.43 close. Shares were trading up slightly at $61.35 as of about 9:45 this morning.

 Second-quarter profits slide 24% for Hill-Rom
Hill-Rom Holdings (NYSE:HRC) posted profits of $25.3 million, or 40¢ per diluted share, on sales of $415.1 million for the 3 months ended March 31.

That compares with profits of $33.1 million, or 52¢ per diluted share, on sales of $402.1 million during the same period last year.
Read more

 Merit Medical’s Q1 profits slide despite sales increase
Merit Medical (NSDQ:MMSI) posted profits of $5.7 million, or 14¢ per diluted share, on sales of $95.6 million for the 3 months ended March 31.

That compares with profits of $6.6 million, or 18¢ per diluted share, on sales of $86.6 million during the same period last year.
Read more

 Sales plunge, losses tick up for NeuroMetrix during Q1
NeuroMetrix (NSDQ:NURO) posted losses of $2.8 million, or 33¢ per share, on sales of $2.1 million for the 3 months ended March 31.

That compares with losses of $2.7 million, or 70¢ per share, on sales of $2.9 million during the same period last year.
Read more

 Palomar’s Q1 losses soar 21% on slow sales growth
Palomar Medical (NSDQ:PMTI) posted losses of $2.3 million, or 12¢ per share, on sales of $19.0 million for the 3 months ended March 31.

That compares with losses of $1.9 million, or 10¢ per share, on sales of $18.2 million during the same period last year.
Read more

 Shire’s DermaGraft sales stay flat
British biotech Shire (NSDQ:SHPGY) said it sold $48.8 million worth of the Dermagraft skin substitute during the 1st quarter. Since Q3 2011, Shire’s reeled in about $143.4 million from the regenerative medicine product ($50 million in Q3 2011, $55 million in Q4 and the $48.8 million logged in Q1 2012).

Overall, Shire posted profits of $238.4 million, or 41¢ per diluted share, on sales of $1.17 billion for the 3 months ended March 31.

That compares with profits of $211.3 million, or 37¢ per diluted share, on sales of $972.2 million during the same period last year.
Read more

 Sorin’s Q1 profits slide
Sorin Group (BIT:SRN) posted profits of $15 million (€191.7M) on sales of $272 million (€191.7M) for the 3 months ended March 31.

That compares with profits of $18 million (€10.6M) on sales of $259 million (€182.3M) during the same period last year.
Read more

 Varian Medical’s Q2 sales, earnings rise
Varian Medical (NYSE:VAR) posted profits of $107.8 million, or 94¢ per diluted share, on sales of $720.3 million for the 3 months ended March 31.

That compares with profits of $103.1 million, or 86¢ per diluted share, on sales of $648.4 million during the same period last year.
Read more

More medical device sales and earnings from MassDevice.com

In case you missed it

RSS From Medical Design & Outsourcing

  • Smith+Nephew expands reach of its Cori handheld robotic system
    A year after Smith+Nephew (NYSE:SNN) launched its Cori handheld robotic system in the U.S.,  the ortho surgery system has launched globally. The British medtech giant has expanded Cori’s reach to Europe, Australia and New Zealand, India, and Canada (just announced today). The company yesterday said the system was now available for use in the U.K.’s National Health… […]
  • Elizabeth Holmes reportedly expresses remorse in criminal fraud trial
    Elizabeth Holmes reportedly revealed some regret over her handling of business as the ex-Theranos CEO took the stand again in a criminal fraud trial. Taking the stand yesterday for the third day of testimony in federal court in San Jose, California, Holmes was said to have shown remorse while still shifting some of the blame… […]
  • Supply chain, manufacturing issues slow Medtronic’s Hugo launch, ramp-up expected next fiscal year
    Medtronic (NYSE:MDT) Chair & CEO Geoff Martha confirmed that the launch of the Hugo surgical robot platform is off-schedule. Hugo received CE mark approval last month. The company is gearing up to conduct its FDA investigational device exemption (IDE) clinical trials in the U.S., with more on its stateside efforts still to come, Medtronic’s surgical robotics… […]
  • Minnetronix Medical honored in Minnesota for its MindsEye Expandable Port
    Minnetronix Medical (St. Paul, Minn.) received an award from the Minnesota Technology Association that highlights its MindsEye Expandable Port for minimally invasive deep brain access. The company won the association’s TEKNE award for best medical technology and devices. “Given Minnesota is a global epicenter for the medical device industry, this award is quite meaningful to Minnetronix… […]
  • BD expands biosciences business with reagent innovation center in San Diego
    A life sciences real estate developer announced today that BD (NYSE:BDX) selected its property as a new facility for its biosciences business. Through a joint venture with Tishman Speyer and Bellco Capital, Breakthrough Properties confirmed that BD chose its Torrey View by Breakthrough property for an expanded San Diego reagent innovation center within its biosciences… […]
  • The best places to work for medtech sales reps in 2022
    Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and Medtronic (NYSE:MDT) topped the list of best places to work in medtech sales in 2022, according to a MedReps.com survey of medical sales representatives. The 11th annual MedReps survey polled over 2,300 MedReps professionals to determine which medtech sales companies are most sought-after in the industry. Overall, pay and leadership were the most… […]
  • How medtech fared in the first waves of the pandemic
    Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data. Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying… […]
  • FreeStyle Libre 3, other Abbott products recognized at CES Innovation Awards
    Abbott (NYSE:ABT) was honored for a handful of its offerings at the Consumer Electronics Show (CES) 2022 Innovation Awards. The company’s FreeStyle Libre 3 continuous glucose monitoring (CGM) system ranked among the top 15 products in the CES Best of Innovation category. The next-generation CGM system features the world’s smallest, thinnest glucose sensor that can… […]
  • Evonik launches new Resomer PrintPowder polymers for 3D printing of personalized, implantable medical devices
    Evonik has launched the second generation of Resomer PrintPowder polymers for 3D printing of personalized, implantable medical devices. Essen, Germany-based Evokik said the powders have a broader range of customizable mechanical properties and degradation rates, allowing their use for more complex and tailored medical devices including orthopedic, dental, or soft tissue applications. “These new powders… […]
  • Tungsten cable for surgical robotics: Challenges solved introduce new unsolved challenges
    Tungsten cable is the perfect strength, flexibility, and diameter for surgical robots. Connor Chiuchiolo and Scott Dailey, Carl Stahl Sava Industries When manufacturing tungsten mechanical cable for surgical robotics, the tungsten itself presents enormous mechanical upside, including extraordinary tensile strength captured within astonishingly small diameters. What’s more, tungsten stranded into ultrafine mechanical cable possesses a remarkable… […]
  • FDA says Philips knew about toxic foam for years before massive recall
    The FDA said it observed potential violations of federal medical device safety rules when inspecting a Philips Respironics manufacturing facility connected to the Class I recall of more than 15 million respiratory devices. The FDA recently requested additional safety testing on replacement materials and issued a Form 483. The form details how Philips and its foam… […]

Leave a Reply